IgEG Platform
Combining IgE and IgG Functionality
- Epsilogen has combined the powerful functionalities of IgE and IgG antibody isotypes
- IgE and IgG are related but structurally/functionally different antibodies
IgEGs: Hybrid IgE/IgG Antibodies
By fusing the CH2-CH3 domains plus the hinge region of IgG to the C terminus of an IgE molecule to create an IgEG
IgEG antibodies have the potential for very high potency by:
- Activating myeloid effector cells such as basophils and macrophages by binding IgE receptors
- Activating Natural Killer (NK) cells by binding Fcg receptors
- Fixing complement
- Possessing extended serum half life by pH-dependent binding to FcRn
In vitro Proof of Concept established
- Express well, fold correctly and bind antigen
- Activate immune cells via engagement with Fcγ receptors
- Activate immune cells via engagement with Fcε receptors
- Bind to FcRn in pH-dependent fashion
Drive both ADCC and ADCP responses
In vivo Proof of Concept established
- NXG mouse/PBMC model with JIMT 1 cell challenge (HER2 low)
- Anti-HER2 IgEGs showed statistically significant tumour growth inhibition (TGI)
- IgEGs work at much lower doses than the equivalent IgG in the NXG mouse model
Half life extension demonstrated in transgenic mouse model
- IgEGs possess greatly elevated serum half life versus IgE
- IgEGs successfully combine long tissue half life of IgE with elevated serum half life of IgG
